Abstract The antidyslipidemic activity of Ocimum sanctum leaf extract was studied in streptozotocin induced diabetic rats. In this model, there was significant increase in plasma markers of diabetic-dyslipidemia following diminution of lipid metabolizing enzymes. Oral administration of leaf extract (500 mg/kg b.w.p.o.) for 15 days resulted in significant decrease in diabetogenic and dyslipidemia parameters; namely blood glucose, glycosylated hemoglobin, lipid peroxide, free fatty acids, small dense low density lipoprotein, lipid and protein components of plasma lipoproteins, adipose and liver. The regulation of lipids was accompanied by stimulation of postheparin lipolytic activity, reactivation of lecithin cholesterol acyl transferase and hepatic lipoprotein lipase enzymes. The results of the present study demonstrated antidyslipidemic and antioxidant activities in leaf extract of O. sanctum which could be used in prevention of diabeticdyslipidemia and related complications.
Introduction
Ocimum sanctum, known as Tulsi in Hindi and Holy Basil in English, is an aromatic-medicinal plant of the genus Ocimum belonging to family Lamiaceae. The plant is native throughout the old world tropics, distributed and cultivated throughout India. Tulsi, well known for its therapeutic potential, has made an important contribution to the field of science from ancient times as also to modern research due to its large number of medicinal properties [1] . It has a variety of biological/pharmacological activities such as antibacterial, antiviral, antifungal, antiprotozoal, antimalarial, anthelmentic, antidiarrhoeal, analgesic, antipyretic, antiinflammatory, antiallergic, antihypertensive, cardio protective, central nervous system depressant, memory enhancer, anti hypercholesterolemic, hepatoprotective, antidiabetic, antiasthmatic, antithyroidic, anti oxidant, anticancer, chemo preventive, radio protective, immunomodulatory, antifertility, antiulcer, antiarthritic, adaptogenic/antistress, anticataract, antileucodermal and anti-coagulant activities [2, 3] . The essential and fixed oils from Ocimum sanctum, containing eugenol and ursolic acid as major constituent, found to possess antidiabetic, cardio protective, vasorelaxant, hypolipidemic and hepatoprotective activities [4] .
It is well established that patients having diabeticdyslipidemia; the disorders of lipid and lipoprotein metabolism associated with diabetes mellitus, are at increased risk of so many vascular complications including cardiovascular diseases (CVD), Cerebrovescular diseases, atherosclerosis, coronary heart disease [5] . These secondary complications in diabetic patients accounts for more than 70 % of all deaths in individuals with diabetes [6] . The centers for diabetes control and prevention reported that 70-97 % of individuals with diabetes have dyslipidemia. Moreover, it is documented that diabetic-dyslipidemia is also associated with increased oxidative stress and displaying impaired normal biological functions and important activities in patients. Therefore, to decrease vascular complications in patients with diabetes, equal effort must be applied to controlling lipid level and oxidative stress as well as blood glucose [7] . The current therapies used for controlling dyslipidemia; fibrates, statins and bile acid sequestraints or antidiabetic drugs; thiazolidinediones, and biguanides are almost inefficient to regulate lipid metabolism. Furthermore, these drugs also cause a number of serious adverse effects in patients. On the other hand since natural products are considered free from side effects, safe and cost effective, being preferred for R&D of potential drugs [8, 9] . This study was, therefore, planned to explore antidyslipidemic activity of Ocimum sanctum leaf extract in streptozotocin induced diabetic-dyslipidemia in rats.
Materials and Methods

Preparation of Leaf Extract
Ocimum sanctum leaves were collected from local area of Lucknow and identified taxonomically by the Department of Pharmacology, Era's Lucknow Medical College and Hospital, Lucknow. A voucher specimen was also submitted. O. sanctum leaves were dried under shade and made into fine powder using laboratory mill. Powder (250 g) was extracted thrice with 500 ml portions of 95 % ethyl alcohol in a percolator at room temperature. Time allowed for each extraction was 4 h. The leaf extract obtained after third extraction was colorless. All the extracts were mixed (1400 ml).Alcohol was distilled out at reduced temperature (20°C) and pressure (100 psi) in a rotatory evaporator. This whole mass was taken out in a pre-weight beaker and subjected to vacuum drying for 6 h. Finally this yielded 16.25 g (6.5 %w/w) of crude extract which was used for in vivo studies. Strerptozotocin (STZ) and standard drug glibenclamide were procured from Sigma Chemical Company; St. Louis, MO, USA. All other chemicals used, were of high purity and analytical grade. Both test drugs were macerated with 1 % (w/v) aqueous gum acacia and a homogeneous suspension of O sanctum leaf extract (50 mg/ml) and glibenclamide (0.6 mg/10 ml) were prepared. These suspensions were fed orally, once daily in experimental rats. The rats in control group were fed with same amount of aqueous gum acacia. The suspensions were prepared fresh daily.
Antidyslipidemic Activity in Streptozotocin Induced Diabetic Rats
Animal study was performed with the approval of Animal Care Committee of Era's Lucknow Medical College and Hospital, Lucknow, India and confirmed to the guide lines for the Care and Use of Laboratory Animals of the Institute. Male adult rats of Wistar strain (200-240 g) bred in the animal house of the Institute were used. A group of six animals in a cage were kept in controlled conditions, temperature 25-26°C, relative humidity 50-60 % and 12/12 h light/dark cycle (light from 08:00 AM-08:00 PM) and provided with standard pellet diet(Dayal Industries, Barabanki, UP, India) and water adlibitum. Diabetes was induced by intraperitoneal injection of streptozotocin (65 mg/kg b.w) in animals [10] .After 3 days of injection, diabetes was confirmed by glucometer. Rats with blood glucose level 300-350 mg/dl were included in the study. Rest of the rats whose blood glucose level was below 300 mg/dl, were rejected. The normal non-diabetic rats were used to serve as control.
Experimental Design
The rats were divided in four groups having six animals in each as follows: Group 1, control rats (on 2 % aqueous gum acacia); Group 2, STZ treated diabetic rats (on 2 % aqueous gum acacia); Group 3, STZ treated diabetic rats ? O. sanctum (500 mg/kg b.w); Group 4, STZ treated diabetic rats ? glibenclamide (600 lg/kg b.w.). After 15 days of feeding, rats were fasted overnight, anaesthetized with thiopental solution, and injected (ip) with 0.1 ml/kg b.w. of 10 mg/ml solution of heparin. After 15 min blood was withdrawn from retro-orbital plexus and collected in EDTA coated tubes. Thereafter rats were sacrificed; their liver and adipose tissue (Abdominal fat pads) were excised.
Biochemical Analysis of Blood and Plasma Lipoproteins
The blood was centrifuged and plasma was separated. The glycosylated hemoglobin (HbA 1C ) in RBC and plasma levels of small dense low density lipoprotein (sd-LDL) were assayed by standard spectrophotometric methods [11, 12] . Plasma was also used for the assay of lecithin cholesterol acyl transferase activity (LCAT), postheparin lipolytic activity (PHLA), glucose, free fatty acid (FFA), lipid peroxide (LPO)by the methods reported earlier [13] . A portion of plasma was fractionated into very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) by polyanionic precipitation methods [14] . Plasma as well as lipoproteins were measured for their total cholesterol (TC), phospholipids (PL), triglyceride (TG) and protein by standard procedures reported earlier [15] .
Biochemical Analysis of Adipose Tissue and Liver
Adipose tissue and liver were homogenized (10 % w/v) in cold 100 mM phosphate buffer pH 7.2 and used for the assay of lipoprotein lipase activity (LPL) as well as TC, PL and TG content in them [15] .
Statistical Analysis
One way analysis of variance (ANOVA-New man's student t test) was performed by comparison of values for STZ treated group with control, STZ and drug treated group with STZ. All hypothesis testing were two-tailed. p \ 0.05 was considered statistically significant and the results were expressed as mean ± SD. The statistical analysis was carried out by the Graph Pad INSTAT 3.0 software.
Results
Effect of O. sanctum in Streptozotocin Induced Diabetic Dyslipidemia
The challenge with streptozotocin (65 mg/kg; ip) caused a significant increase in diabetogenic and dyslipidemia parameters; namely blood levels of glucose by 270 %; HbA 1C , 57 %; LPO, 40 % and free fatty acids, 77 % in rats. Although sd-LDL was not present in control rats, however, it was shown to appear (4.83 mg/dl) in diabetic rats. Treatment with O. sanctum leaf extract and glibenclamide caused reversal in the levels of blood glucose by 32 and 50 %, HbA 1C by 18 and 21 %, LPO by 23 and 20 %, FFA by 35 and 36 % following decrease in the levels of sd-LDL by 38 and 15 % respectively ( Table 1 ). The data in Table 2 The data in Table 3 show that induction of diabetes in rats caused stimulation in LPL activity (79 %) following depletion of TC (31 %), PL (26 %) and TG (48 %) in adipose tissue, however these parameters were partially reversed by 30, 14, 17 and 36 %, respectively, after treatment with O sanctum. On the other hand, in case of liver, the situation was just opposite, where diabetes caused diminution of LPL activity (45 %), which was accompanied with marked accumulation of TC, PL, TG by 67, 52 and 93 % respectively. Treatment with O. sanctum caused reversal in altered levels of hepatic LPL activity, TC, PL and TG by 54, 33, 23 and 34 % respectively. The challenge with streptozotocin also caused the inhibition of PHLA (41 %) and plasma LCAT activity (34 %) which was found reactivated by 27 and 29 %, respectively, in O. sanctum treated diabetic rats. The Antidyslipidemic effect of O. sanctum treatment, on adipose tissue was comparable to that of glibenclamide. However, lowering caused by O. sanctum in the level of hepatic lipids, reactivation of LPL as well as plasma PHLA and LCAT was comparatively more than that of glibenclamide.
Discussion
In the present study, O. sanctum leaf extract was tested for its antidyslipidemic activity in STZ induced diabetes in rats. Challenge with STZ begin an autoimmune process that results in the destruction of langerhans islets b-cells with emergence of clinical diabetes within 2-4 days, and that is why this animal model have been used for primary screening of test drugs for antidiabetic activity [10] . We found that intoxication with STZ caused a significant increase in diabetogenic and dyslipidemia parameters; namely blood glucose, HbA 1C , LPO, FFA and sd-LDL lipid and protein components of plasma lipoproteins, as well as adipose and liver. The abnormality with lipid metabolism was accompanied with diminution of PHLA, LCAT and hepatic LPL activities in rats. Treatment with O. sanctum and glibenclamide for 15 days caused reversal, but with varying extents, in the levels of these biochemical parameters of diabetic-dyslipidemia. In diabetes mellitus, decreased bioavailability of insulin suppresses the utilization of glucose in skeletal muscles and other peripheral tissues thus produces hyperglycemia which causes a variety of pathologic changes through the formation and accumulation of advanced glycation end Values are mean ± SD of six rats. Values in the parenthesis are % change. STZ treated diabetic group is compared with normal rats and STZ ? drug treated groups with diabetic group * p \ 0.05; * p \ 0.01, *** p \ 0.001
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products, increased oxidative stress, activation of protein kinase C pathway, increased activity of hexosamine pathway, vascular inflammation and impairment of insulin action in vascular tissues [16] . Insulin effects on liver apoprotein production and VLDL secretion, regulation of LPL, actions of cholesteryl ester transfer protein (CETP) and lipolysis of fat in adipose tissue and glucose metabolism in muscles. All these complications are likely to be responsible for diabetic-dyslipidemia. Decreased bioavailability of insulin or its resistance to adipocytes, provokes lipolysis of fat depots through activation of hormone sensitive lipase which causes an increase in FFA flux, is very likely the initial step in development of dyslipidemia. The ensuing increase in fatty acid transport to the liver has been shown to stimulate secretion of VLDL. Simultaneously, hyperglycemia induced activation of protein kinase C increases expression of transforming growth factor-b which suppresses the synthesis of glucosaminoglycans in capillary endothelium surface that lead to defect in LPL binding and consequent poor clearance of VLDL in diabetics [17] . The involvement of hyperglycemia may affect the synthesis, also cause structural modifications such as glycosylation and oxidative degradation as well as functional changes in proteins and lipids at any situation. This is also true for CETP and LCAT which are reported to be responsible for abnormalities with HDL metabolism and appearance of sd-LDL in diabetics [18] . Furthermore, structural modifications in lipoproteins made them a defective substrate for their catabolism through LPL and hepatic LDL receptors. Thus characteristic diabetic-dyslipidemia is that of low HDL-cholesterol, hypertriglyceridemia-predominantly in VLDL and presence of high atherogenic sd-LDL particles. Earlier studies have shown that feeding with O. sanctum leaf extract caused lowering in blood sugar levels, serum and tissue lipids in diabetic rats [19] . It regulate carbohydrate metabolism in STZ induced diabetes in rats [20] . The glucose lowering effects of O. sanctum leaf was found to be mediated through its insulin secretagogues effects on pancreas [21] . The phytochemical studies showed that O. sanctum contains a variety of medicinal-chemical compounds. Some of the main constituents of leaf of O. sanctum are phenolic compounds, flavonoids, sesquiterpenes and monoterpenes, glycosides, Steroids, sterols as well as volatile and non volatile, (Fixed) oils [2, 3] . It is suggested that all or some of these bioactive compounds may be responsible for hypoglycemic, antidyslipidemic and antioxidant effects of the medicinal plants [22, 23] . Kelm et al. [24, 25] found that leaves and stems of Ocimum sanctum contains cirsilineol, cirsimaritin, isothymusin, isothymonin, apigenin, rosmarinic acid, and appreciable quantities of eugenol and all these are known to possess potent lipid lowering and antioxidant activities. Suanarunsawat et al. [26] also reported that feeding with essential Values are mean ± SD of six rats. Values in the parenthesis are % change. STZ treated diabetic group is compared with normal rats and STZ ? drug treated groups with diabetic group * p \ 0.05; ** p \ 0.01, *** p \ 0.001 oil extracted from O. sanctum leaf exerted antidiabetic, antidyslipidemic and antioxidant activity in cholesterol fed-hyperlipidemic and STZ-induced diabetic rats. The present work is a detail report on the mechanism of action of O. sanctum leaf to act as an antidyslipidemic agent in STZ induced diabetes in rats. Besides its antidiabetic, antiglycation and antilipoperoxidative effects, the lipid lowering action of O. sanctum may be due to reactivation of, PHLA, LCAT and tissue LPL enzymes. Treatment caused beneficial effect on HDL synthesis that may also contributed to regulate lipid metabolism and to reduce the formation of atherogenic sd-LDL in diabetic rats. The study revealed that O. sanctum is a better drug as a natural product to regress dyslipidemia and oxidative stress in diabetes. Further work to assess the antidyslipidemic activity of different fractions of O. sanctum leaf in STZ induced diabetic rats is under progress to substantiate the present findings.
